Navigation Links
Biopure's Stock Symbol Reverts to BPUR
Date:10/31/2007

CAMBRIDGE, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the trading symbol for its Class A common stock will revert from BPURD to BPUR at the open of the market on Wednesday, October 31, 2007. Outstanding warrants that trade on the OTCBB will revert to the following ticker symbols: BPREW reverting to BPURW; BPREZ reverting to BPURZ; and BPREL reverting to BPURL.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for several other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the only oxygen therapeutic approved by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 186,000 units of Oxyglobin, which have been used to treat an estimated 100,000 animals.

Statements in this release that are not strictly historical are forward- looking statements, including those statements implying that any planned clinical trial will be carried out or that study results will be as desired, statements related to the timing and response of the MHRA review and any statements that might imply that Hemopure may receive marketing approval in additional jurisdictions or for additional indications. Actual results and their timing may differ materially from those projected in these forward- looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue these initiatives, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in or unpredictable outcomes of clinical trials, and the other factors identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q filed on September 14, 2007, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

The content of this release does not necessarily reflect the position or the policy of the U.S. Government or the Department of Defense, and no official endorsement should be inferred.

Contact: Tiana Gorham Herb Lanzet (Investors)

Biopure Corporation H.L. Lanzet Inc.

(617) 234-6826 (212) 888-4570

IR@biopure.com lanzet@aol.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Stockings Effective In Reducing The Effects Of Deep Vein Thrombosis
2. Risk of deep vein thrombosis less in people who were flight stockings when flying
3. Health and Human Services stockpiles 20 million bird flu Vaccines
4. Rich countries stock piling anti flu drugs with no stocks available for poor countries
5. Australian Government To Stockpile Anti-Bird Flu Drug Relenza
6. Bird Flu Threat Prompts Stockpiling Of Food And Medicine In America
7. Wake Up Call: U.N Takes Stock to Curb Fake Medicines Racket
8. Bird flu: the threat causes lowering in poultry stocks
9. OpenMED Nominated For Stockholm Challenge 2006 Award
10. Travel-Related Blood Clots Can Be Reduced By Using Flight Stockings
11. Time is ripe to take stock of depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
Breaking Medicine Technology: